A Phase 3 Single-Arm, Prospective Study of Remestemcel-L, Ex-Vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Steroid Refractory Acute Gvhd in Pediatric Patients
Sonali Chaudhury(Northwestern University), Joanne Kurtzberg, Kris M. Mahadeo(Duke University), Susan E. Prockop(Memorial Sloan Kettering Cancer Center), Jack Hayes(Mesoblast (United States)), Donna Skerrett(Mesoblast (United States)), Steven Neudorf(Children's Hospital of Orange County), Biljana Horn(UF Health Shands Hospital), Eneida R. Nemecek(Oregon Health & Science University)
Cited by 8
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
|Blood|2016|333
The genomic landscape of juvenile myelomonocytic leukemia
|Nature Genetics|2015|310